# US 2014/0194500 A1 · Methods For Treating of SARS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194500 A1
- Document ID: US20140194500A1
- Status: Published application
- Kind: A1
- Application number: 13/736,780
- Filed: 2013-01-08
- Published: 2014-07-10
- Earliest claimed: 2013-01-08
- Assignees: Kookmin University Industry-Academic Cooperation Foundation; Dongguk University Industry-Academic Cooperation Foundation
- Applicants: Kookmin University Industry Academic Cooperation Foundation; Dongguk University Industry-Academic Cooperation Foundation
- Inventors: Young-Sam Keum; Yong-Joo Jeong; Mi-Sun Yu; Young-Won Chin
- Web page: https://patentgrep.com/patent/US20140194500A1

## CPC

- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided is a method of treating SARS in mammals. The method includes administering a therapeutically effective amount of at least one composition selected from the group consisting of myricetin, scutellarein and a pharmaceutically acceptable salt thereof to a mammal in need of treatment of SARS diseases to suppress the activities of SARS coronavirus helicase.

## Claims

### Claim 1

A method of treating SARS in mammals comprising administering a therapeutically effective amount of at least one composition selected from the group consisting of myricetin, scutellarein and a pharmaceutically acceptable salt thereof to a mammal in need of treatment of SARS diseases to suppress the activities of SARS coronavirus helicase.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the composition suppresses the activities of SARS coronavirus helicase nsP13.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the composition suppresses the ATP hydrolysis activity of the SARS coronavirus helicase nsP13.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the mammal is humans.